On July 10, 2020 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, reported that the European Patent Office has issued an Intention to Grant notice for the first European patent covering Anixa’s novel CAR-T cancer treatment technology, which has been licensed from The Wistar Institute and is being developed at the Moffitt Cancer Center (Press release, Anixa Biosciences, JUL 10, 2020, View Source [SID1234561810]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The patent is titled "METHODS AND COMPOSITIONS FOR TREATING CANCER," and the inventors are Drs. Jose Conejo-Garcia and Alfredo Perales-Puchalt. Dr. Conejo-Garcia is the Chair of the Department of Immunology at Moffitt Cancer Center and Dr. Alfredo Perales-Puchalt, formerly of The Wistar Institute, is currently Vice President of R&D at Geneos Therapeutics. The patent is assigned to The Wistar Institute and Anixa Biosciences’ majority-owned subsidiary, Certainty Therapeutics, Inc., is the exclusive, world-wide licensee.
Dr. Amit Kumar, President and CEO of Anixa Biosciences, stated, "We are pleased to receive this notification from the European Patent Office (EPO), and the protection this groundbreaking technology will have throughout the European Union, in addition to the existing patents in the United States. Our CAR-T cancer technology takes advantage of specific hormone–hormone receptor biology to address malignancies and may hold promise to be the first successful CAR-T therapy against solid tumors. While our initial focus is the treatment of ovarian cancer, the technology covered by the patent is broad and may also be effective in treating other solid tumors by exploiting an anti-angiogenesis mechanism of action."
"Protecting intellectual property is critical for the advancement of new therapies, such as our CAR-T technology, which has been exclusively licensed to Anixa’s subsidiary, Certainty Therapeutics. As a minority shareholder of Certainty, we are looking forward to continued advancement of the therapy into the clinic where we hope this will help many cancer patients," said Heather Steinman, PhD, MBA, Vice President of Business Development at The Wistar Institute.